


The claimed invention is:

1. A compound of formula (A):



5

or a pharmaceutically acceptable salt, prodrug, tautomer, hydrate or solvate thereof, wherein:

X is O or S;

- $R^1$  is a saturated, unsaturated, or aromatic C<sub>3</sub>-C<sub>20</sub> mono-, bi- or polycyclic ring optionally containing at least one heteroatom selected from the group consisting of N, O and S, wherein  $R^1$  can optionally be further independently substituted with at least one moiety independently selected from the group consisting of: carbonyl, halo, halo(C<sub>1</sub>-C<sub>6</sub>)alkyl, perhalo(C<sub>1</sub>-C<sub>6</sub>)alkyl, perhalo(C<sub>1</sub>-C<sub>6</sub>)alkoxy, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>2</sub>-C<sub>6</sub>)alkenyl, (C<sub>2</sub>-C<sub>6</sub>)alkynyl, hydroxy, oxo, mercapto, (C<sub>1</sub>-C<sub>6</sub>)alkylthio, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, (C<sub>5</sub>-C<sub>10</sub>)aryl or (C<sub>5</sub>-C<sub>10</sub>)heteroaryl, (C<sub>5</sub>-C<sub>10</sub>)aryloxy or (C<sub>5</sub>-C<sub>10</sub>)heteroaryloxy, (C<sub>5</sub>-C<sub>10</sub>)ar(C<sub>1</sub>-C<sub>6</sub>)alkyl or (C<sub>5</sub>-C<sub>10</sub>)heteroar(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>5</sub>-C<sub>10</sub>)ar(C<sub>1</sub>-C<sub>6</sub>)alkoxy or (C<sub>5</sub>-C<sub>10</sub>)heteroar(C<sub>1</sub>-C<sub>6</sub>)alkoxy, HO-(C=O)-, ester, amido, ether, amino, amino(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkylamino(C<sub>1</sub>-C<sub>6</sub>)alkyl, di(C<sub>1</sub>-C<sub>6</sub>)alkylamino(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>5</sub>-C<sub>10</sub>)heterocyclyl(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkyl- and di(C<sub>1</sub>-C<sub>6</sub>)alkylamino, cyano, nitro, carbamoyl, (C<sub>1</sub>-C<sub>6</sub>)alkylcarbonyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxycarbonyl, (C<sub>1</sub>-C<sub>6</sub>)alkylaminocarbonyl, di(C<sub>1</sub>-C<sub>6</sub>)alkylaminocarbonyl, (C<sub>5</sub>-C<sub>10</sub>)arylcarbonyl, (C<sub>5</sub>-C<sub>10</sub>)aryloxycarbonyl, (C<sub>1</sub>-C<sub>6</sub>)alkylsulfonyl, and (C<sub>5</sub>-C<sub>10</sub>)arylsulfonyl;

each R<sup>3</sup> is independently selected from the group consisting of: hydrogen, halo, halo(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>2</sub>-C<sub>6</sub>)alkenyl, (C<sub>2</sub>-C<sub>6</sub>)alkynyl, perhalo(C<sub>1</sub>-C<sub>6</sub>)alkyl, phenyl, (C<sub>5</sub>-C<sub>10</sub>)heteroaryl, (C<sub>5</sub>-C<sub>10</sub>)heterocyclic, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, hydroxy, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, perhalo(C<sub>1</sub>-C<sub>6</sub>)alkoxy, phenoxy, (C<sub>5</sub>-C<sub>10</sub>)heteroaryl-O-, (C<sub>5</sub>-C<sub>10</sub>)heterocyclic-O-, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl-O-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-S-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-SO<sub>2</sub>-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-NH-SO<sub>2</sub>-, O<sub>2</sub>N-, NC-, amino, Ph(CH<sub>2</sub>)<sub>1-6</sub>HN-, (C<sub>1</sub>-C<sub>6</sub>)alkyl HN-, (C<sub>1</sub>-C<sub>6</sub>)alkylamino, [(C<sub>1</sub>-C<sub>6</sub>)alkyl]<sub>2</sub>-amino, (C<sub>1</sub>-C<sub>6</sub>)alkyl-SO<sub>2</sub>-NH-, amino(C=O)-, aminoO<sub>2</sub>S-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-(C=O)-NH-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-(C=O)-[((C<sub>1</sub>-C<sub>6</sub>)alkyl)-N]-, phenyl-(C=O)-NH-, phenyl-(C=O)-[(C<sub>1</sub>-C<sub>6</sub>)alkyl)-N]-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-(C=O)-, phenyl-(C=O)-, (C<sub>5</sub>-C<sub>10</sub>)heteroaryl-(C=O)-, (C<sub>5</sub>-C<sub>10</sub>)heterocyclic-(C=O)-, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl-(C=O)-, HO-(C=O)-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-O-(C=O)-, H<sub>2</sub>N(C=O)-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-NH-(C=O)-, [(C<sub>1</sub>-C<sub>6</sub>)alkyl]<sub>2</sub>-N-(C=O)-, phenyl-NH-(C=O)-, phenyl-[(C<sub>1</sub>-C<sub>6</sub>)alkyl)-N]-(C=O)-, (C<sub>5</sub>-C<sub>10</sub>)heteroaryl-NH-(C=O)-, (C<sub>5</sub>-C<sub>10</sub>)heterocyclic-NH-(C=O)-, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl-NH-(C=O)- and (C<sub>1</sub>-C<sub>6</sub>)alkyl-(C=O)-O-;

where alkyl, alkenyl, alkynyl, phenyl, heteroaryl, heterocyclic, cycloalkyl, alkoxy, phenoxy, amino of R<sup>3</sup> is optionally substituted by at least one substituent independently selected from (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, halo(C<sub>1</sub>-C<sub>6</sub>)alkyl, halo, H<sub>2</sub>N-, Ph(CH<sub>2</sub>)<sub>1-6</sub>HN-, and (C<sub>1</sub>-C<sub>6</sub>)alkylHN-;


s is an integer from one to five; and

R<sup>4</sup> is selected from the group consisting of: hydrogen, halo, halo(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>2</sub>-C<sub>6</sub>)alkenyl, (C<sub>2</sub>-C<sub>6</sub>)alkynyl, perhalo(C<sub>1</sub>-C<sub>6</sub>)alkyl, phenyl, (C<sub>5</sub>-C<sub>10</sub>)heteroaryl, (C<sub>5</sub>-C<sub>10</sub>)heterocyclic, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, hydroxy, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, perhalo(C<sub>1</sub>-C<sub>6</sub>)alkoxy, phenoxy, (C<sub>5</sub>-C<sub>10</sub>)heteroaryl-O-, (C<sub>5</sub>-C<sub>10</sub>)heterocyclic-O-, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl-O-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-S-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-SO<sub>2</sub>-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-NH-SO<sub>2</sub>-, O<sub>2</sub>N-, NC-, amino, Ph(CH<sub>2</sub>)<sub>1-6</sub>NH-, alkylNH-, (C<sub>1</sub>-C<sub>6</sub>)alkylamino, [(C<sub>1</sub>-C<sub>6</sub>)alkyl]<sub>2</sub>-amino, (C<sub>1</sub>-C<sub>6</sub>)alkyl-SO<sub>2</sub>-NH-, amino(C=O)-, aminoSO<sub>2</sub>-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-(C=O)-NH-,

- (C<sub>1</sub>-C<sub>6</sub>)alkyl-(C=O)-((C<sub>1</sub>-C<sub>6</sub>)alkyl)-N]-, phenyl-(C=O)-NH-,  
 phenyl-(C=O)-((C<sub>1</sub>-C<sub>6</sub>)alkyl)-N]-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-(C=O)-, phenyl-(C=O)-,  
 (C<sub>5</sub>-C<sub>10</sub>)heteroaryl-(C=O)-, (C<sub>5</sub>-C<sub>10</sub>)heterocyclic-(C=O)-, cycloalkyl-(C=O)-,  
 HO-(C=O)-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-O-(C=O)-, H<sub>2</sub>N(C=O)-, (C<sub>1</sub>-C<sub>6</sub>)alkyl-NH-(C=O)-,  
 5 ((C<sub>1</sub>-C<sub>6</sub>)alkyl)<sub>2</sub>-N-(C=O)-, phenyl-NH-(C=O)-, phenyl-((C<sub>1</sub>-C<sub>6</sub>)alkyl)-N]-(C=O)-,  
 (C<sub>5</sub>-C<sub>10</sub>)heteroaryl-NH-(C=O)-, (C<sub>5</sub>-C<sub>10</sub>)heterocyclic-NH-(C=O)-,  
 (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl-NH-(C=O)- and (C<sub>1</sub>-C<sub>6</sub>)alkyl-(C=O)-O-;


where alkyl, alkenyl, alkynyl, phenyl, heteroaryl, heterocyclic, cycloalkyl,  
 alkoxy, phenoxy, and amino of R<sup>4</sup> is optionally substituted by at least one  
 10 substituent independently selected from the group consisting of (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-  
 C<sub>6</sub>)alkoxy, halo(C<sub>1</sub>-C<sub>6</sub>)alkyl, halo, H<sub>2</sub>N-, Ph(CH<sub>2</sub>)<sub>1-6</sub>-NH-, and (C<sub>1</sub>-C<sub>6</sub>)alkylNH-.

2. A compound of claim 1, wherein R<sup>1</sup> is




15


3. A compound of claim 1, wherein R<sup>1</sup> is




4. A compound of claim 1, wherein  $R^1$  is




5. A compound of claim 1, wherein  $R^1$  is



6. A compound of claim 1, wherein  $R^1$  is




7. A compound of claim 1, wherein R<sup>1</sup> is



8. A compound of claim 1, wherein R<sup>1</sup> is

5



9. A compound of claim 1, wherein X is O; s is one to two; R<sup>3</sup> is hydrogen or (C<sub>1</sub>-C<sub>6</sub>)alkyl; and R<sup>4</sup> is H, (C<sub>1</sub>-C<sub>6</sub>)alkyl, or (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl.

10

10. A compound of claim 1, wherein X is S; s is one to two; R<sup>3</sup> is hydrogen or (C<sub>1</sub>-C<sub>6</sub>)alkyl; and R<sup>4</sup> is H, (C<sub>1</sub>-C<sub>6</sub>)alkyl, or (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl.

11. A pharmaceutical composition comprising a compound of claim 1 and a  
15 pharmaceutically acceptable carrier.

12. A method of preventing or treating a TGF-related disease state in an animal or human comprising the step of administering a therapeutically effective amount of

a compound of claim 1 to the animal or human suffering from the TGF-related disease state.

13. A method of claim 12, wherein said TGF-related disease state is selected  
5 from the group consisting of cancer, glomerulonephritis, diabetic nephropathy, hepatic fibrosis, pulmonary fibrosis, intimal hyperplasia and restenosis, scleroderma, and dermal scarring.